Canakinumab  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
Patient  ||| S:20 E:28 ||| NNP
With  ||| S:28 E:33 ||| IN
Difficult-to-Treat  ||| S:33 E:52 ||| NNP
Gouty  ||| S:52 E:58 ||| NNP
Arthritis ||| S:58 E:67 ||| NNP
:  ||| S:67 E:69 ||| :
Review  ||| S:69 E:76 ||| NNP
of  ||| S:76 E:79 ||| IN
the  ||| S:79 E:83 ||| DT
Clinical  ||| S:83 E:92 ||| NNP
Evidence  ||| S:92 E:101 ||| NNP
Many  ||| S:101 E:106 ||| JJ
patients  ||| S:106 E:115 ||| NNS
with  ||| S:115 E:120 ||| IN
gouty  ||| S:120 E:126 ||| JJ
arthritis  ||| S:126 E:136 ||| NN
experience  ||| S:136 E:147 ||| NN
frequent  ||| S:147 E:156 ||| JJ
flares  ||| S:156 E:163 ||| NN
and  ||| S:163 E:167 ||| CC
have  ||| S:167 E:172 ||| VB
comorbidities  ||| S:172 E:186 ||| NNS
that  ||| S:186 E:191 ||| WDT
may  ||| S:191 E:195 ||| MD
limit  ||| S:195 E:201 ||| VB
their  ||| S:201 E:207 ||| PRP$
anti-inflammatory  ||| S:207 E:225 ||| JJ
treatment  ||| S:225 E:235 ||| NN
options  ||| S:235 E:243 ||| NNS
for  ||| S:243 E:247 ||| IN
acute  ||| S:247 E:253 ||| JJ
flare  ||| S:253 E:259 ||| JJ
management ||| S:259 E:269 ||| NN
.  ||| S:269 E:271 ||| .
For  ||| S:271 E:275 ||| IN
patients  ||| S:275 E:284 ||| NNS
with  ||| S:284 E:289 ||| IN
contraindications  ||| S:289 E:307 ||| VBG
to  ||| S:307 E:310 ||| TO
both  ||| S:310 E:315 ||| DT
NSAIDs  ||| S:315 E:322 ||| JJ
and ||| S:322 E:325 ||| CC
/ ||| S:325 E:326 ||| NNP
or  ||| S:326 E:329 ||| CC
colchicine ||| S:329 E:339 ||| NN
,  ||| S:339 E:341 ||| ,
treatment  ||| S:341 E:351 ||| NN
options  ||| S:351 E:359 ||| NNS
are  ||| S:359 E:363 ||| VBP
particularly  ||| S:363 E:376 ||| RB
limited ||| S:376 E:383 ||| VBN
,  ||| S:383 E:385 ||| ,
and  ||| S:385 E:389 ||| CC
there  ||| S:389 E:395 ||| EX
is  ||| S:395 E:398 ||| VBZ
an  ||| S:398 E:401 ||| DT
unmet  ||| S:401 E:407 ||| JJ
medical  ||| S:407 E:415 ||| JJ
need  ||| S:415 E:420 ||| NN
in  ||| S:420 E:423 ||| IN
this  ||| S:423 E:428 ||| DT
subgroup  ||| S:428 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
patients ||| S:440 E:448 ||| NNS
.  ||| S:448 E:450 ||| .
Two  ||| S:450 E:454 ||| CD
phase  ||| S:454 E:460 ||| CD
3  ||| S:460 E:462 ||| CD
studies  ||| S:462 E:470 ||| NNS
and  ||| S:470 E:474 ||| CC
their  ||| S:474 E:480 ||| PRP$
extensions  ||| S:480 E:491 ||| NNS
have  ||| S:491 E:496 ||| VBP
demonstrated  ||| S:496 E:509 ||| VBN
that  ||| S:509 E:514 ||| IN
a  ||| S:514 E:516 ||| DT
single  ||| S:516 E:523 ||| JJ
dose  ||| S:523 E:528 ||| NN
of  ||| S:528 E:531 ||| IN
canakinumab  ||| S:531 E:543 ||| NN
during  ||| S:543 E:550 ||| IN
an  ||| S:550 E:553 ||| DT
acute  ||| S:553 E:559 ||| JJ
flare  ||| S:559 E:565 ||| NN
provided  ||| S:565 E:574 ||| VBD
rapid  ||| S:574 E:580 ||| JJ
and  ||| S:580 E:584 ||| CC
effective  ||| S:584 E:594 ||| JJ
pain  ||| S:594 E:599 ||| NN
relief  ||| S:599 E:606 ||| NN
and  ||| S:606 E:610 ||| CC
prolonged  ||| S:610 E:620 ||| JJ
suppression  ||| S:620 E:632 ||| NN
of  ||| S:632 E:635 ||| IN
flares  ||| S:635 E:642 ||| NN
and  ||| S:642 E:646 ||| CC
inflammation  ||| S:646 E:659 ||| NN
in  ||| S:659 E:662 ||| IN
patients  ||| S:662 E:671 ||| NNS
with  ||| S:671 E:676 ||| IN
a  ||| S:676 E:678 ||| DT
history  ||| S:678 E:686 ||| NN
of  ||| S:686 E:689 ||| IN
frequent  ||| S:689 E:698 ||| JJ
flares  ||| S:698 E:705 ||| NN
and  ||| S:705 E:709 ||| CC
contraindicated  ||| S:709 E:725 ||| NN
for ||| S:725 E:728 ||| IN
,  ||| S:728 E:730 ||| ,
intolerant  ||| S:730 E:741 ||| VBG
of ||| S:741 E:743 ||| IN
,  ||| S:743 E:745 ||| ,
or  ||| S:745 E:748 ||| CC
unresponsive  ||| S:748 E:761 ||| JJ
to  ||| S:761 E:764 ||| TO
NSAIDs  ||| S:764 E:771 ||| JJ
and ||| S:771 E:774 ||| CC
/ ||| S:774 E:775 ||| NNP
or  ||| S:775 E:778 ||| CC
colchicine ||| S:778 E:788 ||| NN
.  ||| S:788 E:790 ||| .
Canakinumab  ||| S:790 E:802 ||| NNP
was  ||| S:802 E:806 ||| VBD
consistently  ||| S:806 E:819 ||| RB
superior  ||| S:819 E:828 ||| JJ
to  ||| S:828 E:831 ||| TO
the  ||| S:831 E:835 ||| DT
active  ||| S:835 E:842 ||| JJ
comparator  ||| S:842 E:853 ||| JJ
triamcinolone  ||| S:853 E:867 ||| JJ
acetonide  ||| S:867 E:877 ||| NN
and  ||| S:877 E:881 ||| CC
was  ||| S:881 E:885 ||| VBD
generally  ||| S:885 E:895 ||| RB
well  ||| S:895 E:900 ||| RB
tolerated  ||| S:900 E:910 ||| VBN
in  ||| S:910 E:913 ||| IN
this  ||| S:913 E:918 ||| DT
patient  ||| S:918 E:926 ||| JJ
population  ||| S:926 E:937 ||| NN
with  ||| S:937 E:942 ||| IN
a  ||| S:942 E:944 ||| DT
high  ||| S:944 E:949 ||| JJ
prevalence  ||| S:949 E:960 ||| NN
of  ||| S:960 E:963 ||| IN
multiple  ||| S:963 E:972 ||| JJ
medical  ||| S:972 E:980 ||| JJ
comorbidities ||| S:980 E:993 ||| NN
.  ||| S:993 E:995 ||| .
Canakinumab  ||| S:995 E:1007 ||| NNP
should  ||| S:1007 E:1014 ||| MD
therefore  ||| S:1014 E:1024 ||| RB
be  ||| S:1024 E:1027 ||| VB
considered  ||| S:1027 E:1038 ||| VBN
as  ||| S:1038 E:1041 ||| IN
a  ||| S:1041 E:1043 ||| DT
treatment  ||| S:1043 E:1053 ||| NN
option  ||| S:1053 E:1060 ||| NN
in  ||| S:1060 E:1063 ||| IN
a  ||| S:1063 E:1065 ||| DT
target  ||| S:1065 E:1072 ||| NN
population  ||| S:1072 E:1083 ||| NN
of  ||| S:1083 E:1086 ||| IN
patients  ||| S:1086 E:1095 ||| NNS
with  ||| S:1095 E:1100 ||| IN
frequent  ||| S:1100 E:1109 ||| JJ
gouty  ||| S:1109 E:1115 ||| JJ
arthritis  ||| S:1115 E:1125 ||| NN
attacks  ||| S:1125 E:1133 ||| NNS
who  ||| S:1133 E:1137 ||| WP
are  ||| S:1137 E:1141 ||| VBP
unable  ||| S:1141 E:1148 ||| JJ
to  ||| S:1148 E:1151 ||| TO
use  ||| S:1151 E:1155 ||| VB
NSAIDs  ||| S:1155 E:1162 ||| JJ
and  ||| S:1162 E:1166 ||| CC
colchicine  ||| S:1166 E:1177 ||| NNS
and  ||| S:1177 E:1181 ||| CC
in  ||| S:1181 E:1184 ||| IN
whom  ||| S:1184 E:1189 ||| WP
frequent  ||| S:1189 E:1198 ||| JJ
use  ||| S:1198 E:1202 ||| NN
of  ||| S:1202 E:1205 ||| IN
corticosteroids  ||| S:1205 E:1221 ||| NN
is  ||| S:1221 E:1224 ||| VBZ
not  ||| S:1224 E:1228 ||| RB
considered  ||| S:1228 E:1239 ||| VBN
appropriate ||| S:1239 E:1250 ||| JJ
.  ||| S:1250 E:1252 ||| .
